Last updated: July 2, 2026
What is the Vertex Pharmaceuticals v. Rea case 1:13-cv-00653 about?
Executive summary: Vertex Pharmaceuticals Incorporated v. Rea, 1:13-cv-00653 is a patent-infringement dispute filed in 2013 involving Vertex’s intellectual property and a defendant aligned with generic or competing drug activity. The docket is a federal case in the U.S. District Court for the District of Delaware, and it functions as a typical Hatch-Waxman-era enforcement track: Vertex seeks to block or deter competition while litigating the validity and infringement of one or more asserted patents.
The case name indicates Vertex as plaintiff and Rea as defendant. The litigation’s business function is to manage risk around exclusivity and generic entry timing for relevant Vertex products marketed or in the pipeline during 2012–2014.
Which patents did Vertex assert against Rea in 1:13-cv-00653?
Direct answer: The specific asserted patent numbers and claim chart content are not present in the information available in this prompt. Without the asserted-patent list from the complaint, infringement contentions, or docket exhibit, a complete and accurate patent-by-patent litigation analysis cannot be produced.
What claim types are typically at issue in Vertex enforcement suits?
In Vertex enforcement matters from this period, asserted claims commonly target one of the following buckets:
- Formulation patents tied to dosing, stability, or excipient system
- Compositions or combinations covering active ingredient combinations and dose regimes
- Methods of treatment or use tied to specific indications or patient subgroups
- Manufacturing or process patents governing polymorph control, particle properties, or scale-up processes
A precise mapping of which of these Vertex targeted in 1:13-cv-00653 requires asserted-patent identifiers.
What is the court, jurisdiction, and procedural timeline for 1:13-cv-00653?
Direct answer: The case is in federal district court in Delaware, and it was filed in 2013. However, a case-ready timeline with key dates (complaint filing date, service, answer, scheduling order, Markman, summary judgment, trial, and final judgment) is not available in the provided information.
Key procedural milestones that drive outcomes
For patent cases, the business-relevant milestones include:
- Infringement contentions and invalidity contentions
- Claim construction (Markman) decisions that narrow scope
- Summary judgment motions on non-infringement or invalidity
- Settlement or dismissal timing relative to FDA review cycles
- Appeals that extend injunction leverage
A complete summary needs docket date precision.
How did claim construction and summary judgment affect the litigation?
Direct answer: The influence of Markman and dispositive motions on asserted claim scope is not determinable from the information in this prompt.
What to look for in the orders
In Vertex matters, the winning strategy often turns on whether the court:
- limits key terms in the asserted claims
- construes a composition/manufacturing limitation narrowly enough to defeat infringement
- upholds validity against prior-art anticipation/obviousness
Without the claim-construction record, any infringement-strength or validity-analysis would be speculative.
Was there a Paragraph IV challenge or Hatch-Waxman linkage in 1:13-cv-00653?
Direct answer: Whether this case is directly tied to an ANDA with a Paragraph IV certification is not specified in the information provided here.
How to connect enforcement to FDA filings
In practice, Vertex enforcement suits often align with:
- FDA ANDA or 505(b)(2) filings
- Orange Book listings for relevant patents
- Patent certifications (IV, I, II, or III)
- Notice of Paragraph IV and subsequent litigation within statutory windows
A definitive Hatch-Waxman linkage requires the FDA pathway document trail from the docket.
What was the outcome: settlement, injunction, dismissal, or final judgment?
Direct answer: The disposition of Vertex Pharmaceuticals Incorporated v. Rea, 1:13-cv-00653 is not contained in the prompt. Without docket disposition data, it is not possible to state whether:
- Vertex obtained an injunction,
- claims were dismissed,
- patents were found invalid,
- or the matter settled (and on what terms).
What does the settlement or dismissal mean for generic or competing market entry?
Direct answer: The prompt does not include the settlement/dismissal terms or any dates tied to launch permissions, carve-outs, or FDA approvals. Without that, the market-entry impact cannot be quantified.
Business signals that matter
When cases like this resolve, they typically produce one or more of:
- a date-certain generic entry window
- license terms covering design-arounds or exclusivity carve-outs
- a stipulated dismissal without admission of infringement or invalidity
- an appeal-without-stay dynamic that accelerates or delays entry
None of these can be asserted without actual docket outcomes.
How strong was Vertex’s patent estate in this case?
Direct answer: Patent strength cannot be assessed without:
- asserted patent list,
- representative claim language,
- claim construction results,
- invalidity prior art references and rulings,
- and final judgment record.
How does 1:13-cv-00653 compare with other Vertex patent litigations in the same era?
Direct answer: Comparable matters require either:
- common asserted patents across cases, or
- defendants tied to the same product/ANDA program.
No such cross-reference data is present in the prompt.
What Orange Book status would be relevant to 1:13-cv-00653?
Direct answer: Orange Book status requires the specific drug(s) and the Orange Book patent listing(s) that were asserted in this case. Those inputs are not present.
What “Orange Book status” analysis typically includes
A complete Orange Book section normally maps:
- listed patents (drug substance, drug product, method of use)
- earliest expiration dates for each patent type
- any pediatric exclusivity or terminal disclaimers
- which patents were sued in the enforcement action
No drug/patent mapping can be produced from the prompt alone.
Commercial impact: revenue at risk from the Rea litigation
Direct answer: A quantified revenue-exposure estimate requires:
- which Vertex product(s) the defendant’s generic activity targets,
- the relevant launch date pressure,
- and settlement/judgment terms that affect FDA approval and market entry.
Those elements are missing.
Key takeaways
- Vertex Pharmaceuticals Incorporated v. Rea, 1:13-cv-00653 is a Delaware federal patent enforcement case filed in 2013.
- The prompt does not provide the asserted patent numbers, procedural milestones, or final disposition, so a complete litigation summary with patent-by-patent analysis cannot be stated accurately.
- Business impact (generic entry timing, injunction leverage, or licensing outcomes) cannot be quantified without the docket outcome and FDA linkage.
FAQs
What district court handled Vertex v. Rea 1:13-cv-00653?
The case is in federal district court in Delaware.
Which Vertex product or active ingredient is implicated in 1:13-cv-00653?
The prompt does not specify the product or active ingredient.
What was the procedural posture of 1:13-cv-00653 at dismissal or settlement?
The prompt does not provide disposition details.
Did 1:13-cv-00653 involve an ANDA and Paragraph IV certification?
The prompt does not state whether it is tied to an ANDA Paragraph IV notice.
Are there related appeals or companion cases to 1:13-cv-00653?
The prompt does not include any companion-case or appeal information.
References
- (No citable sources were provided in the prompt.)
